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Abstract
Prognosis of HIV-1 infection dramatically improved during the last decade. Meanwhile, treatment-
induced virological success has always been different in adult and children patients.
Aim: To compare 10 years of follow up in HIV-1 vertically infected children and adult patients.
Methods: Monocentric retrospective longitudinal analysis of vertically HIV-1-infected children
and adult patients followed in the Nice University Hospital between 1999 and 2008. Immunological,
virological and antiretroviral treatment data were recorded.
Results: Forty children and 1752 adult patients were included. Between 1996 and 2008, the
percentage of children receiving HAART increased from 3.2% to 91%. Mean CD4% in the paediatric
group remained stable between 29 ± 8.1% in 1998 and 30 ± 9.4% in 2008. Mean adult CD4-cell
count signiﬁcantly increased from 410 in 1998 to 556 cells⁄mL in 2008. Logistic regression analysis
showed that the children-to-adult difference for indetectability (HIV PCR-RNA below 400 copies⁄mL)
was signiﬁcant (p < 0.0001) with an odds ratio of 0.61 (CI
95th: 0.52–0.72). Year-to-patient interaction
was also signiﬁcant with a decreasing divergence over time (p: 0.038).
Conclusion: Nowadays as in adult patients, the control of HIV-1 replication is achieved in nearly eight of 10
children and the percentage of patients with severe immunodeﬁciency dramatically decreased compared with
the mid 1990s.
INTRODUCTION
During the mid 1990s, the development of highly active an-
tiretroviral therapy (HAART) resulted in a signiﬁcant
decrease in morbidity and mortality among HIV-infected
children (1). However, in most studies, the percentage of
children achieving undetectable viral load was always lower
than that observed among adult patients in controlled trials
(1,2). The main given reasons were that young children tend
to have higher viral loads and speciﬁc pharmacokinetics
(2). Moreover, few licensed antiretroviral drugs were avail-
able as syrup or paediatric formulation and dosage.
Much progress has been made and pharmacokinetic
studies in younger patients are now available for many
drugs (3,4). Nowadays, the percentage of children achiev-
ing undetectable viral load while receiving HAART is
expected to be similar to that observed among adult HIV-
infected patients (5). To ascertain this assumption, we
reviewed and compared our two local paediatric and adult
databases.
SUBJECTS AND METHODS
Immunological, virological and antiretroviral treatment
data from 40 HIV-1 vertically infected children (25 girls)
followed between February 1995 and October 2008 were
analyzed. The paediatric database was started prospectively
in November 1991. For each consultation the child’s age,
antiretroviral treatment, PCR-RNA HIV-1, CD4 and CD8
cell count and percentage were recorded. Children’s data
were compared with those of adult patients recorded in the
Nadis  database between 1998 and 2008. Nadis  is a com-
puterized medical ﬁle for adult patients infected with HIV,
HBV or HCV, initially activated in November 2000 in Nice
and Toulouse. This database was previously described else-
where (6). For all of the patients from both databases, all
biological analyzes were performed in the same immuno-
logical and virological laboratories. Peripheral blood T-lym-
phocytes and subclass assays (CD4, CD8) were conducted
by ﬂow cytometry. Real-time plasma HIV RNA values
Abbreviations
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Acta Pædiatrica ISSN 0803–5253
ª2009 The Author(s)/Journal Compilation ª2009 Foundation Acta Pædiatrica/Acta Pædiatrica 2009 98, pp. 1787–1792 1787were determined with the Cobas Amplicor  HIV-1 Moni-
tor test (V.1.5) between 1995 and 2004, and with the Cobas
Ampliprep -Cobas TaqMan  HIV Monitor assay (Roche
Diagnostics, Basel, Switzerland) afterwards, according to
the manufacturer’s instructions.
To ensure cohesion during the 10-year period of follow-
up, undetectable HIV-1 viraemia was deﬁned as PCR-RNA
below 400 copies per mL. All of the antiretroviral treat-
ments were prescribed in agreement with the successive
French recommendations [5). Two nucleoside reverse
transcriptase inhibitors (NRTI) and one non-nucleoside
reverse transcriptase inhibitor (NNRTI) or two NRTI
and one protease inhibitor (PI) were considered as HAART
for paediatric treatment. Deﬁnition of HAART was the
same for adult patients apart from those compounds not
yet currently available for children (fusion and integrase
inhibitors).
All values are furnished as mean ± standard deviation.
Statistical analysis was performed with SAS software ver-
sion 9 (SAS Institute Inc., Cary, NC, USA) using a logistic
regression analysis after adjustment for effect (patients * cal-
endar years – Wald Chi-square test). The chi-square test
was used for percentage comparisons (year-to-year compar-
ison of percentages of adult and child patients with unde-
tectable viral load).
RESULTS
Among the 1170 recorded episodes in the paediatric data-
base, 832 were analyzed. Data from patients without treat-
ment were excluded (n = 338). These mainly involved
patients on structured treatment interruption or new
patients before treatment initiation. Thus, between 1995
and 2008, for each patient, an average of 2.6 blood samples
per year was analyzed (1.7 – 4.0). Mean follow up per
patient was 88.7 ± 40.2 months (5.7–152.3).
As expected, the mean age of the paediatric cohort
increased slightly yearly during the observation period
(Table 1). At the time of analysis, two patients had died
from HIV infection, one was lost to follow up in 2005 and
the remaining 37 patients were alive. Fourteen adolescents
were transferred to the adult infectious diseases depart-
ment between 2000 and 2008 after reaching the age of
18 years (Fig. 1). Clinical status according to the paediatric
classiﬁcation (7) was 17, 12 and 11 patients for stages N-
A, B and C respectively. For the adult database, the num-
ber of included patients increased from 1154 to 1732
between 1998 and 2008 for a total count of 15 771 blood
samples.
During the observation period, mean CD4% in the paedi-
atric group remained stable between 29 ± 8.1% (783 ± 351
CD4 T-cells per mL) in 1998 and 30 ± 9.4% (721 ± 322
CD4 T-cells per mL) in 2008 (Table 1, Fig. 2). Meanwhile,
the percentage of samples with severe CD4 T-cell deﬁciency
(deﬁned as below 15%) dropped from 20% in 1997 to 6.3%
in 2007. During the same period, mean adult CD4 T-cell
count increased signiﬁcantly from 410 in 1998 to 556
cells⁄mL in 2008 (Fig. 2).
The mean yearly viral load measured in the paediatric
cohort decreased dramatically from 4.65 ± 0.83 log10
(range: 4.0–5.67) in 1996 to 1.92 ± 0.56 log10 (range: 1.60–
3.43) in 2008 (p < 0.001) (Table 1). Figure 3 displays the
yearly percentage of samples with undetectable viraemia
and compares adult and paediatric values. Chi square analy-
sis showed that the difference was signiﬁcant for the years
2000 (p < 0.001), 2002 (p < 0.005) and 2006 (p < 0.05).
Logistic regression analysis showed that overall, the chil-
dren-to-adult difference for indetectability was signiﬁcant
(p < 0.0001) with an odds ratio of 0.61 (CI95th: 0.52–0.72).
Year-to-patient interaction was also signiﬁcant with a
decreasing divergence over time (Wald Chi-square;
p = 0.038). Figure 4 displays the yearly percentage of time
with undetectable viral loads for the entire cohort of
patients. Thus, during the year 2007, our cohort of patients
had an HIV-1 PCR-RNA below 400 copies per mL for
nearly 80% of the time, assuming the fact that the blood
samples obtained for each patient during the year reﬂected
the true values of the year.
Figure 5 shows treatment strategies provided to adult and
paediatric patients. Between 1996 and 2008, the percentage
of children receiving HAART increased from 3.2% to 91%.
The percentage of PI used in the HAART combinations
decreased from 100% in 1996 to 21% in 2001, then rose to
66% in 2008. NNRTI followed the opposite tendency (none
in 1996; 53% in 2001; 39% in 2008). During the same per-
iod, dual NRTI combination was reduced from 75% to none
of the infected children in 2008.
DISCUSSION
Prospective studies on efﬁcacy, tolerability and safety of
new antiretroviral drugs remain essential to explore and
provide new tools against HIV infection in children. Most
of the HAART-based combinations can achieve sustained
viral suppression and beneﬁcial clinical and immunological
Table 1 Mean yearly age, immunological and virological parameters for the
paediatric cohort
Years Mean age (SD) Mean CD4 (SD) Mean CD4% (SD)
Mean log10
PCR-RNA (SD)
1995 8.2 (2.10) 303 (NA) 16.0 (NA) 4.95 (0.51)
1996 7.7 (2.90) 531 (18.04) 38.8 (18.04) 4.65 (0.83)
1997 8.2 (3.34) 596 (12.30) 22.6 (12.30) 4.24 (1.08)
1998 9.0 (3.22) 783 (8.13) 28.9 (8.13) 3.85 (1.27)
1999 9.3 (4.23) 878 (10.35) 29.2 (10.35) 3.78 (1.22)
2000 10.1 (4.37) 979 (10.80) 29.0 (10.80) 3.26 (1.11)
2001 10.3 (4.52) 934 (9.70) 30.1 (9.70) 2.86 (1.20)
2002 11.6 (4.66) 819 (9.59) 28.0 (9.59) 2.84 (1.27)
2003 10.7 (5.67) 943 (12.57) 31.1 (12.57) 2.6 (1.21)
2004 11.2 (4.72) 874 (9.39) 31.0 (9.39) 2.38 (1.10)
2005 10.6 (4.00) 890 (8.04) 34.2 (8.04) 2.42 (1.06)
2006 11.7 (3.68) 784 (10.55) 31.8 (10.55) 2.38 (0.95)
2007 12.6 (3.42) 701 (9.47) 31.1 (9.47) 1.95 (0.69)
2008 12.1 (4.60) 721 (9.42) 30.1 (9.42) 1.92 (0.56)
All 10.24 (4.37) 795 (10.32) 30.4 (10.32) 3.13 (1.37)
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lation living with AIDS, cross-sectional analysis of viral
suppression showed results far from those obtained in
prospective controlled studies (8–10). Indeed, tolerability
and adherence to treatment may vary in great proportion
resulting in a heterogeneous cohort of patients. Morever, in
paediatric patients, adherence to continuous oral therapy is
not self-directed but usually depends on parental contribu-
tion and conviction. Speciﬁc attention should also be
addressed to HIV-1 chronically infected adolescent
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UPN1  1   6   3   3   3   3   1   2   3  Ped Alive   
UPN2  1   4   2   3   2   4   3   4   2   1   Ad  u   Alive  
UPN3  1   4   2   4   3   4   3   2   1  1   3   Ped Alive   
UPN4  2   4   3   2   3   4   2   2   2   2   3   2   Ped Alive   
UPN5  3   5   5   5   2   Ped Alive   
UPN6  7   3   2   2   3   2   Ped Alive   
UPN7  2   2   1   Ped Alive   
UPN8  2   3   4   1   1   1   2   3   2   2   3   5   Ped Alive   
UPN9  1   2   4   3   5   5   7   6   4   2   Adu Alive   
UPN10   2   2   3   3   Ped Alive   
UPN11   2   3   3   3   3   4   4   Ped Alive   
UPN12   3   4   2   3   2   Ped Alive   
UPN13   1   8   3   2   1   1   2   1   2   3   3   3   3   1   Ped Alive   
UPN14   3   4   3   2   3   2   2   1   2   3   3   2   2   Ped Alive   
UPN15   1   2   2   3   2   5   3   1   1   Adu Alive   
UPN16   2   2   2   3   2   2   3   Ped Alive   
UPN17   1   4   4   9   2   3   2   2   1   4   1   Ped Alive 
UPN18   1   2   4   5   4   3   3   3   1   Adu ?   
UPN19   3   5   4   3   5   4   3   3   3   Adu Dth   
UPN20   1   3   4   2   2   1   Adu ?   
UPN21   1   3   2   2   2   Ped Alive 
UPN22   2   2   3   3   1   2   2   2   Adu ?   
UPN23   1   2   2   3   3   2   ?   Alive 
UPN24   2   2   3   1   Ped Dth   
UPN25   1   4   3   2   1   1   1   2   2   1   Adu Alive 
UPN26   3   2   2   3   3   3   4   3   4   1   Adu Alive 
UPN27   3   4   3   3   2   3   3   2   2   3   4   1   Adu Alive 
UPN28   2   6   4   4   Ped ?   
UPN29   1   2   3   3   2   3   3   1   1   1   Ped Alive 
UPN30   1   3   4   2   Adu ?   
UPN31   2   5   3   3   3   3   2   2   4   3   2   Ped Alive 
UPN32   3   3   4   2   4   2   3   3   2   2   Adu Alive 
UPN33   2   3   3   2  2   1   2   2   Adu Alive 
UPN34   2   3   3   1   1   2   1   3   2   2   2   3   Ped Alive 
UPN35   1   3   2   3   3   1   Ped Alive 
UPN36   4   2   2   2   1   3   2   Ped Alive 
UPN37   3   3   3   2   2   Adu Alive 
UPN38   1   3   2   2   1   3   4   1   Ped Alive 
UPN39   4   Ped Alive 
UPN40   1   1   2   2   3   2   1   5   3   Ped Alive 
Figure 1 Children population and follow up. The number in each cell represents the total number of blood sample available for the patient during the year of
follow-up Ped: follow up in the paediatric department, Adu: follow-up in the adult department, ?: lost to follow-up, Dth: death, : data excluded because of
structured treatment interruption.
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Figure 2 Mean yearly CD4 T-cell counts for adult patients (square) and infected children (triangle).
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Figure 3 Yearly percentage of HIV-1 PCR-RNA <400 copies per mL in adult patients (dot curve) and HIV-1 vertically infected children (continuous curve with mean
and 95th conﬁdence interval).
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Figure 4 Yearly percentage of time with undetectable viral load for the entire paediatric cohort (grey square HIV-1 PCR-RNA <400 copies per mL, blank square HIV-
1 PCR-RNA <40 copies per mL).
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Figure 5 Yearly percentage of bi-therapy and highly active antiretroviral treatment (HAART) in HIV-1 vertically infected children (triangle) compared with adult
patients (square).
Prognosis of HIV-1 infection in children Monpoux et al.
1790 ª2009 The Author(s)/Journal Compilation ª2009 Foundation Acta Pædiatrica/Acta Pædiatrica 2009 98, pp. 1787–1792regarding to adherence as mentioned in most recommenda-
tions (5,9).
Until now, in most phase I⁄II trials of new antiretroviral
drugs, the percentage of children with undetectable viral
load was lower than observed in adults, which is a similar
trend to that observed in young outpatients in clinical prac-
tice. In 2000, the Italian registry showed a major improve-
ment in the survival of perinatally HIV-infected children as
a result of the introduction of combined antiretroviral thera-
pies since 1996. This population-based multicentre observa-
tional study was the ﬁrst paediatric study to provide
information on clinical effectiveness at the population level
(11).
More recently, the study published in 2004 by the Collab-
orative HIV Paediatric Study group from UK and Ireland
(CHIPS) conﬁrms that there are critical differences in the
predictors of immunological and virological response to
HAART in previously untreated children and adults. Over-
all, 60% of their children achieved HIV-1 RNA levels below
400 copies⁄mL within the ﬁrst 6 months of treatment, rang-
ing from 48% in the youngest (<2 years old) to 76% in the
oldest patients. No calendar year of starting HAART effect
was noted (12). Conversely, in a recent update of these
cohorts, only calendar time predicted virological response
in multivariate analysis. For the authors, this discrepancy is
mainly due to a better understanding of HAART manage-
ment together with improved formulations and simpler regi-
men (13).
Our data conﬁrm that henceforward, in industrialized
countries, as is the case with adult patients, most of the
children receiving HAART for HIV infection achieved
control of viral replication. We observed that in <3 years
between 1999 and 2001, the percentage of HIV PCR-
RNA <400 copies per mL increased dramatically in adults
and children from 20–30% to nearly 60–70%. Progression
among children was delayed compared with the situation
observed among adults. There are probably at least two
main reasons for this trend: ﬁrst, the later availability of
paediatric drug formulations for the new antiretroviral
treatments, second, the need for speciﬁc paediatric data
for pharmacokinetics. Variation in immunological status
during the observation period was less obvious. We
mainly observed a marked decrease in the percentage of
children with the most severe immunodeﬁciency (<15%
CD4). In both our adult and paediatric cohort, yearly
evaluation of immune status showed a trend towards
improvement.
Our study is quite different from the COHERE (Collabo-
ration of Observational HIV Epidemiological Research Eur-
ope) study that addressed treatment outcome by age in
49 921 patients ranging from 4 days to 87 years across 30
European countries. Better virological but poorer immuno-
logical responses in older individuals were observed. Mean-
while, as in our study, the chance of experiencing a good
virological response was also associated with calendar per-
iod (8).
We must, however, acknowledge the fact that our study
has a number of limitations. Namely, the small number of
children, our deﬁnition of undetectable viral load now being
replaced by ultrasensitive assays with lower quantiﬁcation
limits (<40–50 copies⁄mL) and unknown or unmentioned
confounders not registered in our databases (B and C hepa-
titis status, gender, route of transmission in the adult data-
base …) must probably be considered.
Morbidity and mortality rates among perinatally HIV-1-
infected children continue to decrease over time as
recently conﬁrmed in the group from UK and Ireland
(12). Meanwhile, nearly 40% of the children aged 15 years
and above have been exposed to drugs from each of the
three main HAART classes (12). Resistance analysis from
the same cohort published elsewhere showed that only
14% of the 166 children with a resistance test had wild-
type virus (13). These data underline the need for real-
time and continuous monitoring of paediatric cohorts to
ensure an optimal transition from paediatric to adult
department. It is therefore important to consider that, as
recently published in a multicohort study, the average
number of years remaining to be lived at the age of 20
dramatically increased since 1996 but remains about two-
thirds of that in the general population of high-income
countries (14).
CONCLUSION
HAART is now recommended as standard treatment regi-
men in both adult and paediatric HIV-infected patients liv-
ing in industrialized countries (5,9). Analysis of our cohort
showed that nowadays the control of HIV-1 replication is
achieved in nearly eight of 10 children and that the percent-
age of patients with severe immunodeﬁciency globally dra-
matically decreased compared with that of mid 1990s.
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